Just remember we have 3 x phase 3, for 3 different products and 3 different applications all due out by the end of the year.
All 3 are expected to have positive results if they mirror the previous study results
All 3 are going to be at least 10 times as big as compared to pediatric SRaGvHD.
The only way we will still be near $10 by the end of the year, is if Ryoncil gets approved, and all 3 phase 3 trials are complete failures.
Any positive phase 3 result from here in represents a much higher share price IMO.
Just remember we have 3 x phase 3, for 3 different products and...
-
- There are more pages in this discussion • 33 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.03 |
Change
0.080(8.42%) |
Mkt cap ! $1.176B | |||
| Open | High | Low | Value | Volume |
| 95.5¢ | $1.03 | 95.0¢ | $43.38M | 42.28M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 72752 | $1.01 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.03 | 205100 | 2 |
View Market Depth
| Last trade - 16.10pm 30/08/2024 (20 minute delay) ? |
| MSB (ASX) Chart |